Cystic fibrosis (CF) is a life-limiting disorder of fluid and electrolyte transport affecting 70,000 individuals worldwide. Patients with CF carry loss of function mutations in each CF Transmembrane conductance Regulator (CFTR) gene. CFTR encodes a cAMP-activated chloride channel that is critical for proper hydration of mucous secretions in the pulmonary airways and pancreatic ducts and maintaining the correct concentration of chloride in sweat. Recently, treatment of CF has taken a major step forward with successful clinical trials of Kalydeco (VX-770), a potentiator compound that increases the function of CFTR bearing the G551D mutation (~2-3% of CF alleles) leading to reduced sweat chloride concentration ([Cl-]) and improved lung function measurements. The success of Kalydeco has fostered the development of numerous other compounds that can correct misfolded forms of mutant CFTR ("correctors") and additional compounds that "potentiate" CFTR that does not conduct chloride at wildtype levels. We now stand at the threshold of being able to treat CF at its root cause;however, there are substantial challenges in delivering molecular therapy to all CF patients. First, there are many different missense and in frame deletion mutations in CFTR (n=816) that a clinical trial for each mutation is not feasible. Second, we don't know if transient increase in CFTR function translates into long-term improvement in lung disease, the major cause of mortality in CF. Third, as lung disease in CF proceeds over many years, we need to gauge effectiveness of CFTR-directed treatment using 'short-term'clinical endpoints. Key preliminary observations suggest that we can address each challenge. CF-causing missense and in frame deletion mutations (n = 47) clustered into groups according to their effect on folding and/or chloride conduction of CFTR appear to correspond to corrector or potentiator responsiveness. Analysis of ~23,000 patients in the CFTR2 database (cftr2.org) revealed that CFTR chloride channel function (as % of wildtype) transformed to a logarithmic scale correlates with cross-sectional lung function (r = 0.43;p = 0.002) and with sweat [Cl-] (r = 0.80;p= 1.3 x 10-11). The overall goal of this application is to inform treatment of CF with CFTR-directed therapies by advancing our understanding of the relationship between CFTR function and clinical manifestations. This goal will be achieved by 1) Classifying CF-causing mutations according to their effect on folding and/or conduction to assess their likely response to current and future CFTR-directed therapeutics;2) Determining the extent to which longitudinal lung function correlates with in vitro CFTR molecular defects and 3) Determining if longitudinal measures of lung function correlate with in vivo CFTR function as measured by sweat [Cl-]. Upon completion of these aims, we will have mined the CFTR2 database and correlated phenotype data with in vitro properties of CFTR mutants to maximize the number of CF patients eligible for CFTR-directed therapy, to estimate the benefit of molecular therapy on long-term lung function in CF patients and to validate the use of sweat gland function to monitor the effectiveness of CFTR-directed treatment.
Cystic Fibrosis (CF) is a life-limiting disorder caused by mutations in the CFTR gene that affects 70,000 individuals worldwide. The overall goal of this proposal is to understand the consequences of different mutations upon the function of CFTR and the severity of CF. This information will be invaluable in predicting outcome for CF patients and evaluating the potential of therapies targeted at specific mutations in CFTR.
|Sosnay, Patrick R; Siklosi, Karen R; Van Goor, Fredrick et al. (2013) Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet 45:1160-7|
|Sosnay, Patrick R; Castellani, Carlo; Corey, Mary et al. (2011) Evaluation of the disease liability of CFTR variants. Methods Mol Biol 742:355-72|
|Blackman, Scott M; Hsu, Stephanie; Vanscoy, Lori L et al. (2009) Genetic modifiers play a substantial role in diabetes complicating cystic fibrosis. J Clin Endocrinol Metab 94:1302-9|
|Krasnov, Kristina V; Tzetis, Maria; Cheng, Jie et al. (2008) Localization studies of rare missense mutations in cystic fibrosis transmembrane conductance regulator (CFTR) facilitate interpretation of genotype-phenotype relationships. Hum Mutat 29:1364-72|
|Buranawuti, Kitti; Boyle, Michael P; Cheng, Suzanne et al. (2007) Variants in mannose-binding lectin and tumour necrosis factor alpha affect survival in cystic fibrosis. J Med Genet 44:209-14|
|Sheridan, Molly B; Fong, Peying; Groman, Joshua D et al. (2005) Mutations in the beta-subunit of the epithelial Na+ channel in patients with a cystic fibrosis-like syndrome. Hum Mol Genet 14:3493-8|
|Hefferon, Timothy W; Groman, Joshua D; Yurk, Catherine E et al. (2004) A variable dinucleotide repeat in the CFTR gene contributes to phenotype diversity by forming RNA secondary structures that alter splicing. Proc Natl Acad Sci U S A 101:3504-9|
|Groman, Joshua D; Hefferon, Timothy W; Casals, Teresa et al. (2004) Variation in a repeat sequence determines whether a common variant of the cystic fibrosis transmembrane conductance regulator gene is pathogenic or benign. Am J Hum Genet 74:176-9|
|McWilliams, Rita; Hoover-Fong, Julie; Hamosh, Ada et al. (2003) Problematic variation in local institutional review of a multicenter genetic epidemiology study. JAMA 290:360-6|
|Swiatecka-Urban, Agnieszka; Duhaime, Marc; Coutermarsh, Bonita et al. (2002) PDZ domain interaction controls the endocytic recycling of the cystic fibrosis transmembrane conductance regulator. J Biol Chem 277:40099-105|
Showing the most recent 10 out of 26 publications